Funding
← Back to your selection

IQ Capital

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
Rounds participated in
3
Confirmed lead rounds
1
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$77.7M
3 disclosed · full round size, not this investor’s share

By stage

Seed2
Series A1

By primary sector

Biotech3

By country

United Kingdom3

Rounds

3 in this selection
Undecimal Bio

Undecimal Bio develops delivery molecules that help RNA medicines reach specific tissues, with initial research programmes in kidney and vascular disease.

$18MSeed
Lead
IMU Biosciences

Profiles human immune systems using multi-omic analysis and machine learning for disease research.

$53MSeries A
Role not disclosed
Imperagen

Uses quantum physics simulation and AI to engineer high-performance enzymes for pharma and industrial markets

£5MSeed
Role not disclosed